Axa acquired a new stake in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 130,484 shares of the company’s stock, valued at approximately $3,520,000. Axa owned approximately 0.36% of Biohaven Pharmaceutical at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Legal & General Group Plc acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter valued at $119,000. Nationwide Fund Advisors purchased a new position in Biohaven Pharmaceutical in the third quarter valued at $214,000. American International Group Inc. purchased a new position in Biohaven Pharmaceutical in the third quarter valued at $251,000. State of Wisconsin Investment Board purchased a new position in Biohaven Pharmaceutical in the third quarter valued at $262,000. Finally, Susquehanna International Group LLP purchased a new position in Biohaven Pharmaceutical in the third quarter valued at $302,000. Institutional investors and hedge funds own 61.84% of the company’s stock.
Several equities analysts recently commented on BHVN shares. Canaccord Genuity started coverage on Biohaven Pharmaceutical in a report on Friday, December 15th. They issued a “buy” rating and a $30.00 target price on the stock. Zacks Investment Research lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Piper Jaffray Companies set a $48.00 target price on Biohaven Pharmaceutical and gave the company a “buy” rating in a report on Monday, December 11th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Biohaven Pharmaceutical in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $38.57.
In other Biohaven Pharmaceutical news, CFO James Engelhart sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $32.50, for a total transaction of $325,000.00. Following the transaction, the chief financial officer now owns 13,576 shares of the company’s stock, valued at $441,220. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Declan Doogan sold 121,942 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $26.78, for a total value of $3,265,606.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 837,976 shares of company stock worth $24,007,425.
Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) opened at $27.22 on Friday. The stock has a market capitalization of $981.48 and a PE ratio of -4.99. Biohaven Pharmaceutical Holding Co Ltd has a twelve month low of $17.00 and a twelve month high of $39.51.
COPYRIGHT VIOLATION NOTICE: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://ledgergazette.com/2018/03/18/axa-acquires-shares-of-130484-biohaven-pharmaceutical-holding-co-ltd-bhvn.html.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.